NY-AQARA
23.6.2022 09:03:12 CEST | Business Wire | Press release
Aqara, a leading provider for smart home products, released its Hub M1S Gen 2, which is an enhanced version of the brand’s iconic smart home control center Hub M1S. Enabled with new hardware and software updates, the Hub M1S Gen 2 inherits most features from its predecessor, and improves the network security by adopting the WPA3 standard. It also adds configurable ringtones, allowing users to create more customized home automations. The new hub is now available on the Aqara Amazon stores in the EU (France , Germany , Italy and Spain ) and via authorized Aqara retailers worldwide*, and the availability will expand to North America (the US and Canada) in the following months.
Similar to other Aqara hubs, the Hub M1S Gen 2 is a control center within the Aqara ecosystem, and connects other Aqara Zigbee devices to the Wi-Fi network. It manages and controls smart scenes as well as smart devices, such as switches, plugs, curtains, roller shades, and so on. The M1S Gen 2 adopts the Zigbee 3.0 protocol, supporting up to 128 Aqara devices**. Moreover, it allows the connected child devices to be compatible with major third-party ecosystems including HomeKit, Alexa, Google and IFTTT. The M1S Gen 2 is expected to receive the Matter OTA update after the Matter rollout, allowing the connected Aqara accessories to work with other Matter-compatible devices.
Key features of the Hub M1S Gen 2 include:
- A powerful built-in 2-watt speaker allowing the hub to be used for sirens, doorbells, and custom ringtones;
- A built-in RGB light ring with configurable brightness and color, allowing the hub to serve as a night light or an accent light;
- A fully functional illumination sensor that can be used for automations on the Aqara Home app;
- Enhanced Wi-Fi connectivity with the powerful 2x2 MIMO Wi-Fi antenna and the WPA3 standard support, enabling the faster, secure and reliable connection;
- The new hub supports all 4 modes of the HomeKit Security System, which automatically sync with the Alert System on the Aqara Home app.
For more details of the Hub M1S Gen 2, please visit our website .
* Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
** To connect up to 128 Aqara child devices, repeater devices such as Smart Plug or Wall Switch (with Neutral) are required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom